KW-2449 (KW2449) is a novel, potent, multiple-kinase (e.g. FLT3/Bcr-Abl/FGFR/Aurora) inhibitor with potential antitumor activity.

Alisertib (also named as MLN8237, MLN-8237) is a novel potent, selective, orally bioavailable Aurora A kinase (AAK) inhibitor with potential antitumor activity.

CCT129202 (CCT-129202), an imidazopyridine compound, is a potent and ATP-competitive pan-Aurora inhibitor with potential antitumor activity.

Barasertib ( INH34; AZD1152 or AZD1152-HQPA) is a novel, potent, highly selective, orally bioavailable small-molecule Aurora B inhibitor with potential antitumor activity.

SNS-314 (SNS314) is a novel, potent and selective, synthetic small molecule inhibitor of Aurora A/B/C with anticancer activity.

TAK-901 (TAK901) is a novel and potent inhibitor of Aurora A/B kinases with potential antitumor activity.

CCT137690 is a novel, potent, highly selective and orally bioavailable inhibitor of Aurora kinase A/B/C with potential antitumor activity.

GSK1070916 (also known as NMI-900 or GSK-1070916A) is a novel, potent, reversible and ATP-competitive inhibitor of Aurora B/C with potential antitumor activity.

PHA-680632 (PHA680632) is a novel and potent pan-aurora kinase inhibitor with potential antitumor activity.

SNS-314 mesylate, the mesylate salt of SNS314, is a pan-Aurora kinase inhibitor with potential antineoplastic activity.